Losartan recall expands — again

Vivimed Life Sciences issued a recall for 19 lots of losartan potassium tablets after detecting a potentially carcinogenic impurity.

The affected drugs, known as angiotensin receptor blockers, come in 25 milligram, 50 milligram and 100 milligram tablets. They were distributed to wholesale, retail and mail order pharmacies by Heritage Pharmaceuticals.

The losartan potassium tablets were found to have unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid.

Vivimed announced its recall May 3. The recall list continues to grow. Teva Pharmaceuticals, Legacy Pharmaceutical Packaging and Torrent Pharmaceuticals already have recalled lots of losartan.

Read the full recall notice here.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>